A Phase 1 Study of TAK-925 to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Danavorexton (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Takeda
- 25 Sep 2019 According to a Takeda Pharma media release, data from this study was presented at the World Sleep 2019 Biennial Congress in Vancouver, Canada.
- 25 Sep 2019 Results published in the Takeda Pharma Media Release
- 10 Sep 2018 Status changed from recruiting to completed.